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ABSTRACT 
 
Cytomegalovirus is a virus of paradoxes and can be a potential killer or a silent lifelong companion. The CMV 
infection in immunocompromised patients carries high morbidity and mortality. CMV infection is a common 
opportunistic viral infection among HIV/AIDS patients. This research therefore aimed at Studying Cytomegalovirus 
infection among HIV Positive Patients Attending Infectious Diseases Hospital, Kano, to ascertain the seroprevalence 
of specific CMV IgM antibodies among HIV positive patients and to correlate the infection rate with immune status 
(CD+4count) of the patients. A total of 207 clients who were reactive to HIV-1/HIV-2 antibodies were enrolled in the 
study. Sera samples were screened serologically for the presence of specific CMV IgM antibodies by using microwell 
ELISA kits manufactured by Immunodiagnostics Inc. Out of 207 HIV positive patients, 27 (13.0%) were seroreactive to 
the specific CMV IgM antibodies of which 9 (4.3%) were males and 18 (8.7%) were females. Patients with low CD+4 
lymphocyte(< 100 cells/µl) were more infected by CMV.-High seroprevalence of specific CMV IgM antibodies was 
found among HIV patients and therefore monitoring of HIV patients with low CD+4 counts for the presence of specific 
CMV IgM antibodies may be of paramount importance to identify those at risk of CMV disease so as to carry 
prophylactic treatment before they develop clinical manifestation of CMV disease (end organ disease).   
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INTRODUCTION  
 
Cytomegalovirus (CMV) is ubiquitous herpes virus that generally causes asymptomatic or mildly symptomatic 
infections in immunocompetent hosts. In contrast, the CMV infection in immunocompromised patients carries 
high morbidity and mortality (Springer and Weinberg, 2004). All herpes viruses share a characteristics ability to 
remain latent within the body over a long period (Ryan and Ray, 2004).  
Human Immunodeficiency Virus (HIV) causes progressive impairment of the body’s cellular immune 
system leading to increased susceptibility to infections and tumours, and a fatal condition known as Acquired 
Immunodeficiency Syndrome (AIDS) (Cheesbrough, 2005). HIV infects cells bearing the CD4 antigen receptor, 
the most important being T – helper lymphocyte (CD4 T = cells). These cells regulate cellular and humoral 
immunity by interacting with other T – lymphocytes, B – lymphocytes, macrophages and natural killer cells. When 
CD+4 positive T – cells are depleted, immune defences are weakened (Cheesbrough, 2005). 
Cytomegalovirus (CMV) is a widely distributed opportunistic agent seen with AIDS (Akinbami et al., 
2010).It is a beta – herpesvirus; the major cause of non – Epstein – Barr virus infectious mononucleosis in the 
general population and an important pathogen in immune-compromised hosts, including patients with AIDS, 
’neonates and the transplant  recipients (Krech, 1973). In most people with a fully functional immune system, the 
initial infection with CMV may cause a mild flu like illness and later the virus remains dormant. A damaged 
immune system permits the reactivation of CMV. A synergistic effect may worsen the progression in HIV infected 
persons (Chakravarti et al., 2009). During advanced AIDS, CMV can produce debilitating end – organ disease 
(EOD) including retinitis, colitis, and pneumonitis. Previous to the HAART (highly active antiretroviral therapy) 
era, some studies observed that the rates of the CMV EOD among the patients with advanced HIV infection were 
approximately 40% or greater (Basawaraju et al., 2011). With the advent of HAART, the incidence of the CMV 
EOD has reduced (Basawaraju et al., 2011).  
Sexual transmission appears to be the most common route of infection in adults, though CMV can also 
be spread through Oropharyngeal secretions, urine, breast milk and blood (Akinbami et al., 2010). Most patients 
with AIDS who develop clinical signs and symptoms of CMV infection probably have reactivation of previous 
infection rather than primary infection (Klatt and Shibata, 1988).  
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The prevalence of HIV/AIDS in sub – Saharan Africa is high but, the description of CMV infection as an 
opportunistic infection amongst patients is scanty (Akinbami et al., 2010). Akinsola et al. (1997) have reported a 
few cases of CMV retinitis in HIV infected Nigerians. 
Antibody testing can be used to determine if someone has had recent or past exposure. IgM antibodies 
are the first to be produced by the antibody in response to a CMV infection. They are present in most individuals 
within a week or two after the initial exposure. On the other hand, IgG antibodies are produced by the body 
several weeks after the initial infection. Antibody testing and viral CMV detection may be used to help diagnose 
primary CMV infection in young adults, pregnant women, and some immunocompromised people. By comparing 
the presence or absence of IgG and/or IgM in the sample, active and latent CMV infection can be ascertained 
(Lab. Test online, 2012). Hence, the aim of this study was to determine the presence of specific CMV IgM 
antibodies in immunocompromised subjects. 
 
 
MATERIALS AND METHODS  
 
This cross sectional study was carried out at Infectious Diseases Hospital (IDH), Kano. A heterogenous two 
hundred and seven (207) HIV – positive volunteers that filled informed consent form were enrolled into the 
investigation from January, 2011 to December 2011 after obtaining ethical clearance from the State Hospital 
Management Board ethical committee irrespective of their sex, age, educational and socioeconomic background. 
There were no patients that received primary or secondary CMV prophylaxis as CMV prophylaxis are often not 
administered in Nigeria. 
Five millilitres of blood was collected into sterile plain bottle, the samples were centrifuged at 3000 rpm 
for 5 minutes, sera separated into sterile bottles on each collection day, for storage at – 200C prior to the time 
when the assay was carried out. Another 5ml was collected into EDTA bottle for CD4 counts at the same day of 
collection. Screening for CMV IgM specific antibodies was done using commercial ELISA kit. 
  The cut-off optical density (O.D) was obtained in accordance with the manufacturer’s instructions, the 
CMV index of the samples was calculated by dividing the O.D value of each of the samples with the obtained 
Cut-off O.D value (C.OD). 
 
S/C.OD      Interpretation 
CMV index<0.90    Negative 
CMV index 1.0 and above                                  Positive 
 
 
CD+4 Estimation 
 
CD4 was determined using an automated Cyflow CD4+ cell counter. Twenty microlitre (20ul) CD+4perierythene 
antibody was added into partec test tube (Rohren tube) followed by twenty microlitre (20ul) of well mixed whole 
blood, mixed gently and incubated in the dark for 15 minutes at room temperature. Eight hundred microlitre 
(800ul) of CD+4buffer was added and also mixed gently. The tube was then plugged on the sensor for counting. 
 
 
RESULTS  
 
A total of 207 HIV positive patients were enrolled in the study of which 70 (33.8%) were males while 137 (66.2%) 
were females. Total number of positive cases was found to be 27(13%).The infective/reactive rate was 
significantly higher among females 18 (8.7%) than in males 9 (4.3%). 
Table 1 summarizes percentage frequency distribution of the studied population. Out of the 207 patients 
screened for the study, 27(13.0%) were reactive to specific CMV IgM antibody whereas 180 (87%) were not.  
Table 2 indicates the distribution of specific CMV IgM antibodies in relation to sex; among the male 
respondents, 9 (4.3%) were reactive while 61(29.5%) were non reactive. Among the females, 18(8.7%) were 
reactive and 119(57.5%) were non reactive. The infective/reactive rate was significantly higher among females 18 
(8.7%) than in males 9 (4.3%) (P > 0.01) (Table 2). 
The distribution of specific CMV IgM antibodies in relation to age was also ascertained (Table 3), the 
highest occurrence was found in the 21 – 30 age group 10 (4.8%) while the lowest being 11-20 and 61 – 70 age 
brackets 1(0.5%).  
Distribution of specific CMV IgM among HIV – patients in relation to their CD+4 lymphocyte counts is 
presented in Table 4.  Patients with CD+4 lymphocyte counts of less than 100 cells/µl shows the highest 
susceptibility to CMV with 19 (9.2%) followed by those that have CD+4 lymphocyte count of 100 - 350 cells/µl with 
7 (3.4%) infected while the least susceptibility was shown by those that have CD+4 lymphocytes counts of greater 
than 350 cells/µl with only 1 (0.48%) patient infected with CMV.  
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Table 1: Distribution of Specific CMV IgM Antibodies among HIV Patients 
 Frequency  Percentage (%) 
Reactive  27 13 
Nonreactive  180 87 
Total  207 100 
 
 
Table 2: Distribution of Specific CMV IgM Antibodies in Relation to Sex 
Sex Reactive (%) Nonreactive (%) Total (%) 
Male 9 (4.3) 61 (29.5) 70 (33.8) 
Female 18 (8.7) 119 (57.5) 137 (66.2) 
Total  27 (13.0) 180 (87.0) 207 (100.0) 
 
 
Table 3: Distribution of Specific CMV IgM Antibodies in Relation to age 
Age group (years) Reactive (%) Nonreactive (%) 
11 – 20  1 (0.5) 9 (4.3) 
21 – 30  10 (4.8) 58 (28.1) 
31 – 40 6 (2.9) 65 (31.4) 
41 – 50 4 (1. 9) 35 (16.9) 
51 – 60 5 (2.4) 11 (5.3) 
61 – 70 1 (0.5) 1 (0.5) 
71 – 80 0 (0.0) 0 (0.0) 
81 – 90 0 (0.0) 1 (0.5) 
Total (%) 27 (13.0) 180 (87.0) 
 
 
Table 4: Distribution of Specific CMV IgM Antibodies in Relation to CD+4 Count of HIV Patients 
CD+4 Count (cells/µl) Reactive (%) Non reactive (%) 
< 100 19 (9.2) 36 17.4) 
100 – 350 7 (3.4) 107 (51.7) 
> 350 1 (0.48) 37 (17.9) 
Total (%) 27 (13.0%) 180 (87.0) 
 
 
DISCUSSIONS 
 
The CMV active infection might be a marker of extremely severe immunosuppresion, which may ultimately lead 
to a fatal outcome in the patients. The presence of the IgM antibodies may be due to primary infection, 
reactivation or re-infection by CMV (Chakravarti et al., 2009).  
In this study, the specific CMV IgM antibodies seropositivity was found to be 27(13%). This prevalence is 
on the high side when compared to developing countries (8.0-8.5%) (Ray and Mahajan, 1997; Hizal et al.,1972). 
It is equally higher than the world range (0 – 10%) (Turbadkar et al., 2000). The prevalence rate is higher when 
compared to work done by Akinbami et al. (2010) (6.6%) in his study among immunocompromised (HIV) patients 
at Lagos University Teaching Hospital. It is high when compared to  the work of Basawaraju et al. (2011) (9.52%) 
that carried out his study among AIDS patients in India. The prevalent rate does not correlate with those of 
Chakravarti et al. (2009); Chakravarti et al. (2010); Mujtaba et al. (2003); and Vajpayee et al. (2005) in India in 
which they have observed positivity rates of about 3 – 10%. It is slightly high when compared to the  work done 
by Neusa et al. (1998) in Brazil among HIV infected prison inmates where prevalent rate of 11.36% was reported. 
It is however lower, when compared to the work done by Tsertsvadze et al (2002) where prevalent rate of 19 
(14%) among HIV patients was reported. Racial differences between the populations, enormous cultural and  
economic  differences between developed countries (where the study  was previously carried out) and 
developing countries like Nigeria are valid factors that might be responsible for this variation in prevalent rate 
obtained as also reported by Neto et al. (2004); and Nishimura et al. (1999).  
The study revealed that females living with HIV are more susceptible to specific CMV IgM antibodies 
than their male counterparts; female subjects showed high prevalent rate of 18 (8.7%) than males 9(4.3%). The 
infective/reactive rate was significantly higher among the females than in the males (P > 0.01). 
Seropositivity of specific CMV IgM antibodies in relation to different age groups revealed that CMV 
antibodies are high between age groups 21 – 30 and 31 – 40 years. This finding is in concordance with the study 
conducted by Okwori et al. (2008). This trend could be attributed to the fact that the above mentioned age groups 
represent active and sexually matured youths with the tendency towards sexual promiscuity and its resultant 
likelihood of high infection rates (Zhong and Ma, 1999).  
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The result obtained in the study showed that, HIV patients with CD+4 count < 100 cell/µl showed high prevalence 
of specific CMV IgM antibodies which is in concordance with other studies that showed the risk of CMV disease 
is highest when the CD+4 count is < 100 cells/µl and it is rare when the count is greater than 100 cells/µl (Cunha 
et al. 2002). Likewise, it has been shown that CD+4 lymphocytes levels below 50 cells/µl are important markers in 
the prognosis of the clinical manifestation of CMV and that they also indicate a disease phase which is frequently 
defined as advanced AIDS (Chakravarti et al., 2009). The correlation analysis between CD+4 lymphocytes count 
and specific CMV IgM antibodies distribution among HIV positive patients was found to be positive but non-
significant. 
 
 
CONCLUSION 
 
The study reveals high prevalent rate (13%) of CMV IgM antibodies among HIV positive patients. Equally, it 
shows that the number of females living with HIV are higher (8.7%) than their male counterparts with prevalent 
rate of 4.3% and that CMV antibodies are highest among HIV patients with CD+4 count less than 100 cells/µl, 
hence, the distribution of the specific CMV IgM antibodies among studied population is high among HIV patients 
in the study population.  
 
 
RECOMMENDATION 
 
It is important  that  patients are tested for specific  CMV IgM antibodies  and also specific  CMV IgG antibodies in 
order to identify those at risk of CMV disease that are HIV positive with low CD4+ counts.  
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